The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Breast Cancer Liquid Biopsy Market From 2026 To 2030?
The breast cancer liquid biopsy market has experienced substantial expansion in recent years. Its growth is projected from $0.89 billion in 2025 to $1.02 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. The market’s historical development can be attributed to factors such as rising breast cancer prevalence, limitations of tissue biopsy, oncology diagnostic advancements, increased screening awareness, and laboratory testing expansion.
The breast cancer liquid biopsy market is anticipated to experience substantial growth in the coming years. It is projected to achieve a value of $1.75 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.3%. This expansion during the forecast period is attributed to factors like the adoption of precision oncology, AI-based mutation analysis, personalized treatment planning, an increase in cfDNA testing, and the rise of decentralized cancer diagnostics. Significant trends expected during this period include multi-biomarker blood-based testing, non-invasive cancer monitoring, treatment response tracking, early recurrence detection, and personalized oncology diagnostics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp
Which Drivers Are Advancing The Breast Cancer Liquid Biopsy Market Growth?
The rising incidence of breast cancer is anticipated to stimulate the expansion of the breast cancer liquid biopsy market moving forward. Breast cancer is defined as a malignancy originating in breast cells, frequently in the lobules (glands producing milk) or ducts (channels transporting milk to the nipple). The upward trend in breast cancer diagnoses stems from various contributors such as genetic susceptibility, disruptions in hormone levels, an older demographic, shifts in lifestyle, excess weight, alcohol intake, insufficient exercise, radiation exposure, and contaminants in the environment. In a therapeutic context, a breast cancer liquid biopsy serves to identify circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) within the bloodstream, enabling continuous disease monitoring. This method assists in evaluating how patients respond to treatment, recognizing when therapies become ineffective, and pinpointing genetic alterations for specific, targeted treatments. For example, the American Cancer Society, a US-based nonprofit organization focused on cancer research, education, advocacy, and patient support, projects an increase in new breast cancer cases to 319,750 in 2025, an increase from 313,510 cases in 2024. Consequently, the expanding number of breast cancer instances is propelling the growth of the breast cancer liquid biopsy market.
What Are The Major Segment Categories Within The Breast Cancer Liquid Biopsy Market?
The breast cancer liquid biopsy market covered in this report is segmented –
1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
What Trends Are Influencing The Breast Cancer Liquid Biopsy Market?
Key companies operating in the breast cancer liquid biopsy market are prioritizing the creation of advanced products, such as companion diagnostics, to support personalized treatment strategies by identifying patients most likely to benefit from specific therapies. These companion diagnostics leverage liquid biopsy technologies to detect biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions, which indicate treatment responsiveness. For example, in January 2023, Guardant Health Inc., a US-based biotechnology company, secured Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test. This test serves as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval empowers oncologists to utilize the test for comprehensive genomic profiling, thereby pinpointing patients who could benefit from the targeted treatment. It represents Guardant Health’s first U.S. Food and Drug Administration (FDA) approval in breast cancer, enhancing its involvement in precision oncology.
Which Key Players Are Active In The Breast Cancer Liquid Biopsy Market?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc
Access The Complete Breast Cancer Liquid Biopsy Market Report:
https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report
Which Region Holds The Largest Share In The Breast Cancer Liquid Biopsy Market?
North America was the largest region in the breast cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Breast Cancer Liquid Biopsy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp
Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2026, By The Business Research Company
Liquid Biopsy Market Report 2026
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report
Breast Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Biopsy Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model